Welcome to our dedicated page for Haoxi Health Technology SEC filings (Ticker: HAO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Haoxi Health Technology Limited (HAO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Haoxi files reports with the U.S. Securities and Exchange Commission, including annual reports on Form 20-F and current reports on Form 6-K, which together describe its online marketing business focused on healthcare advertiser clients in China.
In these filings, Haoxi explains how it generates revenue from one-stop online marketing solutions, including traffic acquisition from mainstream online media platforms, content production, data analysis, and advertising campaign optimization. The financial statements detail cost of revenue, which the company states is primarily driven by the purchase of online traffic from third-party media platforms and salaries and benefits for business operation staff, as well as selling, general and administrative, and research and development expenses related to its Bidding Compass online ads bidding analysis software.
Filings on Form 6-K also cover capital markets and corporate actions, such as follow-on public offerings, private placements of Class A ordinary shares, and the 1-for-25 reverse share split approved by shareholders. Other 6-K reports describe securities purchase agreements, the closing of private placements, and notices of shareholder meetings, including extraordinary general meetings.
On Stock Titan, each new Haoxi Health Technology Limited filing is captured from EDGAR and paired with AI-powered summaries that highlight key points, such as changes in share capital, use of proceeds from offerings, and updates on listing status or corporate governance matters. Users can quickly review complex documents, locate information on share structure and financing transactions, and understand how Haoxi’s regulatory disclosures relate to its digital advertising operations in the healthcare sector.
Haoxi Health Technology Ltd director Liu Jia has filed an initial insider ownership report on Form 3. The filing identifies Liu Jia as a director of the company and, in the provided data, shows no reported transactions, share purchases or sales, and no listed derivative positions.
Haoxi Health Technology Limited reported a change in its board of directors. On March 6, 2026, director Jianbing Zhang resigned from the board for personal reasons, and the company stated that his resignation did not involve any disagreement over operations, policies, or practices.
The board appointed Chuanjie Hu as a new director effective the same day and determined he meets the “independence” requirements of Nasdaq and Rule 10A-3. Mr. Hu will chair the nominating and corporate governance committee and serve on the compensation and audit committees, and will not receive compensation for his board service.
Haoxi Health Technology Limited has terminated its at-the-market equity offering program with Aegis Capital Corp. The program had allowed the company to offer and sell up to $80 million of Class A ordinary shares under an effective Form F-3 shelf registration and related prospectus supplement.
Haoxi and Aegis entered into a mutual termination agreement effective February 7, 2026, ending the sales agreement and related arrangements. The company reports that it did not sell any Class A ordinary shares under this at-the-market program before it was terminated.
Haoxi Health Technology Limited established an at-the-market equity offering program that allows it to sell Class A ordinary shares with an aggregate offering price of up to
The company entered into a Sales Agreement with Aegis Capital Corp., which will act as sales agent and use commercially reasonable efforts to sell shares based on Haoxi’s instructions, through methods qualifying as an “at the market offering” under Rule 415.
Haoxi will pay the sales agent a commission of
Haoxi Health Technology Limited is offering up to
The company plans to use net proceeds for general corporate purposes, including working capital, operating expenses, capital spending, potential acquisitions and business development. Haoxi is a Cayman Islands holding company whose operations run through its PRC subsidiary, Haoxi Beijing, an online marketing solutions provider focused on healthcare advertisers, which generated
The filing highlights substantial legal and operational risks tied to doing business in China, including evolving foreign investment, data security and CSRC overseas listing rules that could limit offerings or even render the shares worthless. It also notes potential HFCA Act delisting risk if PCAOB access to the auditor were ever restricted, PRC constraints on moving cash out of China, the absence of planned dividends, emerging growth and foreign private issuer status, and an auditor report expressing substantial doubt about the company’s ability to continue as a going concern.
Haoxi Health Technology Limited filed a Form 6-K announcing that materials for an Extraordinary General Meeting of Shareholders are available. The filing attaches the Notice and Proxy Statement as Exhibit 99.1 and the Proxy Card as Exhibit 99.2.
The company notes it is a foreign private issuer and that the Notice is not subject to SEC review and comment. Shareholders are urged to read the Notice for important details about the meeting. Copies are available on the SEC’s website at www.sec.gov and on the company’s website at http://www.haoximedia.com/.
The company, its Board, and executive officers may be deemed participants in the proxy solicitation, with additional information about their interests described in the Notice.
Haoxi Health Technology Limited closed a Regulation S private placement to non‑U.S. persons, issuing 5,217,391 Class A ordinary shares at $0.23 per share for gross proceeds of $1.2 million. The transaction closed on October 22, 2025, and net proceeds will be used for working capital and general corporate purposes.
Following the closing, shares outstanding were 7,503,028 Class A and 690,800 Class B, each with a par value of $0.0025, as of the date of this report. The shares were issued in reliance on the Securities Act’s Regulation S exemption.
Haoxi Health Technology Limited (HAO) filed its annual report on Form 20-F. The Cayman holding company operates in China through its subsidiary, providing one-stop online marketing solutions, especially short video ads, mainly for healthcare clients. It also launched livestreaming agency services in April 2025, which have not generated revenue.
The company completed an IPO at $4.00 per share, including an over-allotment, for total gross proceeds of $11,040,000. A 25-for-1 share consolidation and share capital reorganization took effect on January 10, 2025, setting authorized capital at 300,000,000 Class A and 100,000,000 Class B shares, each with $0.0025 par value. An aggregate of 2,896,595 ordinary shares were outstanding as of June 30, 2025 (2,205,795 Class A; 690,800 Class B).
The report highlights PRC regulatory risks, including CSRC filing requirements for overseas offerings. The company completed CSRC filing for its IPO in 2023 and filed regarding a follow-on in 2024. No dividends have been paid; future earnings are intended for reinvestment. Auditor Wei, Wei & Co., LLP is PCAOB-inspected, addressing HFCA Act risks noted.
Haoxi Health Technology entered a securities purchase agreement to raise capital through a private placement. On October 13, 2025, the company agreed to sell 5,217,391 Class A ordinary shares for an aggregate purchase price of approximately $1.2 million to certain non‑U.S. investors under Regulation S. The company plans to use the proceeds for working capital and general corporate purposes.
The agreement includes customary representations and warranties and is subject to various conditions to closing, including the accuracy of the parties’ representations. The shares are being offered in a transaction exempt from U.S. registration. A form of the Securities Purchase Agreement was filed as an exhibit.